Instructions

Instructions / Instruction for use: Solcoseryl Injection

Trade name of the drug – Solcoseryl

Dosage form: solution for intravenous and intramuscular administration
Composition.Composition per 1 g
Active ingredient:
Solcoseryl (dialysate from the blood deproteinized dairy calves) in terms of dry matter - 42.5 mg
Auxiliary components:
water for injections

Description
The clear solution, from slight yellow to yellow. Characteristic Solcoseryl slight odor (smell of broth).

Pharmacotherapeutic group- Tissue repair stimulator

ATC code Â05ZA

Pharmacological Properties

The Solcoseryl drug is deproteined hemo-dialysate containing a wide range of low-molecular components of cell mass and blood serum of dairy calves with a molecular weight of 5,000 D (glycoproteins, nucleosides and nucleotides, oligo-peptides, amino acids).
It was established that Solcoseryl has the following properties:

  • Solcoseryl improves the transport of oxygen and glucose to the cells in hypoxic conditions;
  • It increases intracellular synthesis of ATP and increases the proportion of aerobic glycolysis and oxidative phosphorylation;
  • Solcoseryl activates regenerative and reparative processes in the tissue;
  • It stimulates fibroblast proliferation and collagen synthesis vessel walls.

Pharmacokinetics
With the help of the pharmacokinetic methods is impossible to study the pharmacokinetic parameters Solcoseryl drug.
Indications

- Disorders of peripheral arterial and venous circulation (peripheral arterial occlusive disease stage III-IV by Fontaine, chronic venous insufficiency, accompanied by trophic disorders);
- Violation of cerebral metabolism and blood flow (ischemic and hemorrhagic stroke, traumatic brain injury).

Contraindications
- Established hypersensitivity to bovine blood dialysate;
- Solcoseryl contains as derivatives of parahydroxybenzoic acid (E 216, E 218) used as a preservative as well as trace amounts of benzoic acid (E 210), the drug should not be used in the presence of allergic reactions to these components;

- Children up to age 18 years (due to lack of data);

- Pregnancy and lactation (due to lack of data).

Precautions: hyperkalemia, renal failure, cardiac arrhythmias, concomitant drugs potassium (since Solcoseryl contains potassium); oliguria, anuria, pulmonary edema, severe heart failure.

Dosing and Administration
Intravenously (previously diluted with 250 ml of 0.9% sodium chloride or 5% dextrose), slow intravenous (previously diluted with 0.9% sodium chloride or 5% dextrose in sodium ratio 1: 1), intramuscular,
Peripheral arterial occlusive disease in stages III-IV on Fontaine: 20 ml daily intravenously. Duration of therapy up to 4 weeks and is determined by the clinical picture of the disease.Chronic venous insufficiency with trophic disturbances: 10 ml intravenously 3 times a week. Duration of therapy is no more than 4 weeks and is determined by the clinical picture of the disease. If you have a local trophic disorders of tissues recommended therapy with simultaneous Solkoseril gel and then Solcoseryl ointment.Traumatic brain injury, metabolic and vascular diseases of the brain: 10-20 ml intravenously daily for 10 days. Then, 2 mL intramuscularly or intravenously to 30 days.
If intravenous administration is not possible, the drug may be administered by intramuscular injection of 2 ml per day.

Side effect
In rare cases can develop an allergic reaction (hives, redness and swelling at the injection site, fever). In this case, you must stop using the product and assign an expected treatment.

Overdose (intoxication) drug
For information about the symptoms of an overdose are not available.

Interaction with other drugs
Solkoseryl should not be confused when administered with other drugs (especially phytoextracts).Pharmaceutical incompatible with parenteral forms extract Ginko biloba, Naftidrofuryl, Bencyclane fumarate .

With caution used with drugs that increase the level of potassium in the blood (potassium supplements, potassium-sparing diuretics, angiotensin-converting enzyme).
Release Form
Solution for intravenous or intramuscular administration of 42.5 mg / ml. 2 or 5 ml ampoules made of neutral hydrolytically stable dark glass (Class I on Evr.F.) with white point above the point where the fault. 5 vials in contour cell polymer upakovku.1 outline packaging with the drug in 5 ml ampoules or 5 outline packages with the drug in 2 ml ampoules, together with instructions for use in a cardboard box.
Storage conditions
At a temperature of 15 to 25 ° C. Keep out of the reach of children.

Shelf life
5 years. Do not use the drug after the expiry date stated on the package.
Conditions of supply of pharmacies
On prescription.